Mutagenic potential of cis-dichlorodiammine platinum II in rodents.
The ability of cis-dichlorodiammine platinum II to cause chromosomal aberrations in rats and dominant lethality in mice was studied. Five daily intraperitoneal doses ranging from 0.25 to 2.00 mg/kg/day failed to result in the observance of dominant lethal mutations in mice. Intraperitoneal doses of 0.13 and 0.52 mg/kg/day for 5 days in rats did, however, cause chromosomal aberrations in bone marrow cells collected and harvested 24 h after the last dose. The incidence of total aberrations observed at the 0.52 mg/kg/day dose level was 5.5-fold greater than that seen for the vehicle control group. Thus, cis-dichlorodiammine platinum II appears to be clastogenic in rats.
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D002869:Chromosome Aberrations; D002945:Cisplatin / Q000494:pharmacology*; D005260:Female; D005799:Genes, Dominant / Q000187:drug effects; D005804:Genes, Lethal / Q000187:drug effects; D008297:Male; D051379:Mice; D009153:Mutagens; D011247:Pregnancy; D051381:Rats
D009153:Mutagens; D002945:Cisplatin